Table 2 Effect of tocilizumab on oxygen therapy and PO2/FiO2 ratio
From: Safety and efficacy of tocilizumab in critically ill patients with COVID-19: an observational study
O2 therapy after 48 h | Total | P value* | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Nasal cannula (3–6L) | Nasal cannula (< 3L) | NRHF | Face mask (< = 10L) | CPAP | MV | Died | ||||
O2 therapy before | NRHF | 16 | 0 | 0 | 8 | 7 | 4 | 3 | 38 | < 0.001 HS |
Nasal Cannula | 0 | 4 | 2 | 0 | 1 | 1 | 0 | 8 | ||
CPAP | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | ||
Total | 17 | 4 | 2 | 8 | 8 | 6 | 5 | 50 | ||
PO2/FiO2 after 48 h | ||||||||||
< 200 | > 200 | Total | P value* | |||||||
PO2/FiO2 before | < 200 | 25 | 17 | 42 | 0.01 HS | |||||
> 200 | 4 | 4 | 8 | |||||||
Total | 29 | 21 | 50 | |||||||